Orbis and Novo Nordisk sign oral macrocycle discovery partnership worth up to $1.4 billion
Company / institutional announcement · Orbis Medicines / Novo Nordisk
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Orbis Medicines and Novo Nordisk signed a multi-target discovery and licensing agreement for orally bioavailable macrocycles in cardiometabolic disease. Orbis is eligible for up to $1.4 billion in upfront and future milestone payments, plus royalties, and Novo will make a strategic investment. Separate upfront and investment amounts were undisclosed; the headline value is not cash already paid.
Why it may matter
Strengthens cardiometabolic interest in oral macrocycle discovery while leaving target identities and the distribution of actual payments unresolved.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections